Full metadata record
DC FieldValueLanguage
dc.contributor.authorHo, Shu-Yien_US
dc.contributor.authorChen, Pin-Rongen_US
dc.contributor.authorChen, Chia-Hungen_US
dc.contributor.authorTsai, Nu-Manen_US
dc.contributor.authorLin, Yu-Hsinen_US
dc.contributor.authorLin, Chen-Sien_US
dc.contributor.authorChuang, Cheng-Hsunen_US
dc.contributor.authorHuang, Xiao-Fanen_US
dc.contributor.authorChan, Yi-Linen_US
dc.contributor.authorLiu, Yen-Kuen_US
dc.contributor.authorChung, Chen-Hanen_US
dc.contributor.authorWeng, Shun-Longen_US
dc.contributor.authorLiao, Kuang-Wenen_US
dc.date.accessioned2020-07-01T05:21:20Z-
dc.date.available2020-07-01T05:21:20Z-
dc.date.issued2020-04-09en_US
dc.identifier.urihttp://dx.doi.org/10.1186/s12951-020-00610-9en_US
dc.identifier.urihttp://hdl.handle.net/11536/154407-
dc.description.abstractBackground The anti-angiogenic fusion protein RBDV-IgG1 Fc (RBDV), which comprises the receptor-binding domain of vascular endothelial growth factor-A (VEGF-A), has shown antitumour effects by reducing angiogenesis in vivo. This study used the cationic lipoplex lipo-PEG-PEI-complex (LPPC) to simultaneously encapsulate both the RBDV targeting protein and the RBDV plasmid (pRBDV) without covalent bonds to assess VEGFR targeting gene therapy in mice with melanoma in vivo. Results LPPC protected the therapeutic transgene from degradation by DNase, and the LPPC/RBDV complexes could specifically target VEGFR-positive B16-F10 cells both in vitro and in vivo. With or without RBDV protein-targeting direction, the pRBDV-expressing RBDV proteins were expressed and reached a maximal concentration on the 7th day in the sera after transfection in vivo and significantly elicited growth suppression against B16-F10 melanoma but not IgG1 control proteins. In particular, LPPC/pRBDV/RBDV treatment with the targeting molecules dramatically inhibited B16-F10 tumour growth in vivo to provide better therapeutic efficacy than the treatments with gene therapy with IgG1 protein targeting or administration of a protein drug with RBDV. Conclusions The simultaneous combination of the LPPC complex with pRBDV gene therapy and RBDV protein targeting might be a potential tool to conveniently administer targeted gene therapy for cancer therapy.en_US
dc.language.isoen_USen_US
dc.subjectLPPCen_US
dc.subjectGene therapyen_US
dc.subjectAnti-angiogenesisen_US
dc.subjectRBDVen_US
dc.subjectVEGFRen_US
dc.titleLipoplex-based targeted gene therapy for the suppression of tumours with VEGFR expression by producing anti-angiogenic moleculesen_US
dc.typeArticleen_US
dc.identifier.doi10.1186/s12951-020-00610-9en_US
dc.identifier.journalJOURNAL OF NANOBIOTECHNOLOGYen_US
dc.citation.volume18en_US
dc.citation.issue1en_US
dc.citation.spage0en_US
dc.citation.epage0en_US
dc.contributor.department交大名義發表zh_TW
dc.contributor.department生物科技學系zh_TW
dc.contributor.department分子醫學與生物工程研究所zh_TW
dc.contributor.departmentNational Chiao Tung Universityen_US
dc.contributor.departmentDepartment of Biological Science and Technologyen_US
dc.contributor.departmentInstitute of Molecular Medicine and Bioengineeringen_US
dc.identifier.wosnumberWOS:000527696900001en_US
dc.citation.woscount0en_US
Appears in Collections:Articles